Business Context and Reporting Period
Company: Medirom Healthcare Technologies Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: July 10, 2024
Principal Office: Tokyo, Japan
This filing reports the entry into acquisition agreements on June 30, 2024, to acquire a controlling interest in Japan Gene Medicine Corporation ("JGMC").
Key Financial Metrics and Transaction Details
Acquisition Structure:
- Initial Acquisition: Purchase of 70% of JGMC's issued and outstanding shares.
- Purchase Price: ¥2,000,000 thousand (approx. ¥2 billion) in cash.
- Valuation Methodology: Based on a hypothetical Adjusted EBITDA for the year ended December 31, 2023, multiplied by 6x, adjusted for economic benefits from subcontracted services, and scaled to 70% ownership.
- Financing: The Company intends to fund the majority of the purchase price via bank loans. Negotiations are ongoing.
Option to Acquire Remaining Shares:
- Target: Remaining 30% of JGMC shares.
- Deadline: Must be completed prior to June 30, 2027.
- Pricing Formula: Based on JGMC's Adjusted EBITDA for the fiscal year ending December 31, 2026, multiplied by a factor of 6 (or 7 if Adjusted EBITDA exceeds ¥930,000 thousand), minus outstanding borrowings, plus cash balances, scaled to 30%.
Financial Metrics Provided: The filing does not provide Medirom's current revenue, profit, cash flow, or debt levels. It only references JGMC's hypothetical Adjusted EBITDA used for valuation.
Material Changes and Conditions
Conditions Precedent to Closing:
- Obtaining a bank letter of commitment for financing exceeding 70% of the Initial Acquisition Purchase Price.
- Amendment of subcontracted testing and analysis service agreements between JGMC and seller-affiliated companies to ensure economic benefits accrue to JGMC.
Operational Covenants:
- Seller must cooperate in JGMC management for at least five years post-closing to achieve performance targets.
- Medirom must retain existing JGMC employees for one year post-closing.
Outlook, Risks, and Contingencies
Management Commentary: The transaction is expected to make JGMC a subsidiary of Medirom. The Company is actively negotiating bank loan terms to fund the acquisition.
Risks and Contingencies:
- Financing Risk: The transaction is contingent on securing bank financing; failure to do so may prevent closing.
- Seller's Repurchase Option: If Medirom records negative net assets or net income for two consecutive fiscal years, or undergoes a substantial management change, the seller may repurchase 101 shares of JGMC (approx. 20% of outstanding shares) at fair market value. This could reduce Medirom to a minority owner.
- Put Option: If Medirom does not exercise its option to buy the remaining 30%, the seller may demand Medirom sell back all or part of its JGMC holdings at fair market value.
- Indemnification Cap: Damages for breach of representations are capped at ¥10,000 thousand per party.
Investor Verification Checklist
- Verify the status of bank loan negotiations and the likelihood of securing financing exceeding 70% of the purchase price.
- Confirm the progress of amending subcontracted service agreements to ensure economic benefits flow to JGMC.
- Review Medirom's current liquidity and debt capacity to assess the impact of the new debt load.
- Monitor JGMC's financial performance to evaluate the potential valuation of the remaining 30% option.
- Assess the risk of the Seller's Repurchase Option triggering if Medirom faces consecutive years of negative net income or assets.